John Celebi has over 20 years of experience building innovative entrepreneurial biotechnology companies.  Previously, Mr. Celebi served as the Chief Operating Officer of X4 Pharmaceuticals where he established and oversaw the company’s oncology business strategy.  He also served as Chief Business Officer of Igenica Biotherapeutics, Inc., an immunotherapy company formed by The Column Group, 5AM Ventures, Orbimed and Third Rock Ventures, where he established key academic and industry relationships, including with MedImmune.  He has extensive transactional and alliance management experience. Previously, he served as Vice President of Business Development, New Product Planning and Alliance Management at ArQule, Inc., where he played a central role in the formation of alliances with Roche, Daiichi-Sankyo, and Kyowa Hakko Kirin.  Mr. Celebi was one of the early employees at Tularik, Inc., where he conducted drug discovery and basic research for an anti-viral drug program. Mr. Celebi received an M.B.A. from Carnegie Mellon University and a B.S. in Biophysics from the University of California, San Diego.

Dr. Fuller has over 30 years of experience in the pharmaceutical and biotechnology industries working on a range of therapeutic and diagnostic products. Prior to joining Panacea, Dr. Fuller served as Vice President, Product and Process Development at Nabi Biopharmaceuticals, Inc. While at Nabi, he held positions of increasing responsibility in the development, GMP manufacture, quality control, quality assurance and clinical testing of vaccine and immune globulin products for infectious disease and drugs of addiction. Dr. Fuller was an integral part of a team that filed two biologics license applications for immunotherapeutic products and also filed numerous Investigation New Drug (IND) applications for vaccine products. At ADI Diagnostics, Inc., Toronto, Ontario, Dr. Fuller was Director of Operations for ADI’s diagnostics development and manufacturing of tests for cancer and infectious disease.  He is author of numerous peer-reviewed publications and multiple patents. Dr. Fuller received his B.S. degree in Biology from Wheaton College and his Ph.D. in genetics from Michigan State University.

Edward Garmey, M.D. is an experienced oncology drug development consultant and based in Cambridge, MA. Dr. Garmey was formerly Chief Medical Officer and Senior Vice President at Cerulean Pharma, Inc., a clinical-stage oncology company. Under his tenure at Cerulean, the company completed a successful IPO NASDAQ:CERU) in April, 2014, and its clinical group, while increasing in size from one to 12 employees including three oncologist M.D.s, launched eight clinical trials and brought its second experimental drug into the clinic. Dr. Garmey also served as Vice President for Clinical Development at ArQule, Inc. (2008–2011), a cancer-focused biotechnology company where he developed and oversaw multiple international clinical trials of its lead product, ARQ 197 (tivantinib). A pediatric hematologist-oncologist by training, Dr. Garmey is a graduate of Harvard and New York Universities and completed his medical training at the Mount Sinai Medical Center (N.Y.); the Children’s Hospital of Los Angeles; and the Memorial Sloan Kettering Cancer Center (N.Y.). Dr. Garmey completed additional research fellowships at the National Institutes of Health (1998–99) and Botswana-Harvard Partnership for H.I.V. Research in Gaborone, Botswana (1999–2000) and he is a recipient of young investigators awards from the American Society of Hematology and the American Heart Association. Dr. Garmey has presented at numerous international conferences and is an author on over 50 peer-reviewed abstracts and manuscripts. He resides near Boston, Massachusetts, where he serves as an adjunct instructor at Harvard Medical School’s Therapeutics Graduate Program and additionally as a member of the Board of Overseers at the Beth Israel Deaconess Medical Center.

Hossein Ghanbari is a co-founder of Sensei Biotherapeutics and currently serves as its Chief Science Officer and Board Chair.  He served as Chairman, CEO and CSO of the company until February 2018 during which he led the company into clinical studies with SNS-301 and was instrumental in raising significant financing for the company.  Dr. Ghanbari began his career in the pharmaceutical industry at Abbott Laboratories in Chicago, where he developed several pharmaceuticals and the first ever commercialized diagnostic test for Alzheimer’s Disease (AD).  He was part of the New Drug Application (NDA) team for Leupron, the successful prostate cancer drug, as well as for Survanta, the current drug of choice for preventing and treating respiratory distress syndrome in premature infants.  He directed the Analytical sections of the Investigational New Drug (IND) application for an antibody-based antiviral drug and was a member of Abbott’s Technical Advisory Board.  Dr. Ghanbari was inducted into the prestigious honorary organization, the Volwiler Society, established by Abbott to recognize the company’s most distinguished and accomplished scientists.  After nearly a decade with Abbott, Dr. Ghanbari left to form Molecular Geriatrics Corporation, (a biopharma company focused on developing drugs for neurodegenerative diseases) and served as its Senior Vice-President for R&D.  Subsequently, Dr. Ghanbari was instrumental in establishing Nymox Pharmaceutical Corporation (NASDAQ: NYMX), and served as Senior Vice-President for R&D and Strategic Planning as well as a Director on its board.  While with Nymox, he developed the first commercially available cerebral spinal fluid- and urine-based diagnostics tests for Alzheimer’s Disease (AD) and identified opportunities for complementary technologies that Nymox in-licensed, which together established the company’s international presence as a leader in AD diagnostics and therapeutics.  Prior to entering private industry, Dr. Ghanbari held professorships at Pennsylvania State University, University of Florida, and Arya-Mehr University of Technology (now Sharif University).  He was also on the academic staff of The George Washington University School of Medicine and Health Sciences as an Adjunct Professor.  He currently serves as a Board member of the Gastric Cancer Foundation.  Dr. Ghanbari received his Bachelor of Sciences degree, with distinction, from the American University in Beirut, and his master’s and doctorate degrees in Biochemistry from Pennsylvania State University.  He has authored over 70 peer reviewed publications, and is an inventor on nearly 100 patents and patent applications worldwide.

Dr. Lebowitz has more than 20 years of experience in biomedical research within the biotech industry having previously served as the Director of Research at 20/20 GeneSystems, Inc. and Vice President of Research at Ariadne Diagnostics, LLC.  He was a leader in the research leading up to the IND approval of Sensei Bio’s lead vaccine candidate, SNS-301, and the commercial launch of six cancer diagnostic tests.  Dr. Lebowitz holds a Ph.D. from the Johns Hopkins University School of Medicine in Biochemistry, Cellular, and Molecular Biology where he subsequently completed a three-year fellowship in immunology in the Department of Pathology, Division of Immunopathology. He is an adjunct Lecturer in the Advanced Academic Program in Biotechnology within the Krieger School of Arts and Sciences at JHU.

John Celebi has over 20 years of experience building innovative entrepreneurial biotechnology companies.  Previously, Mr. Celebi served as the Chief Operating Officer of X4 Pharmaceuticals where he established and oversaw the company’s oncology business strategy.  He also served as Chief Business Officer of Igenica Biotherapeutics, Inc., an immunotherapy company formed by The Column Group, 5AM Ventures, Orbimed and Third Rock Ventures, where he established key academic and industry relationships, including with MedImmune.  He has extensive transactional and alliance management experience. Previously, he served as Vice President of Business Development, New Product Planning and Alliance Management at ArQule, Inc., where he played a central role in the formation of alliances with Roche, Daiichi-Sankyo, and Kyowa Hakko Kirin.  Mr. Celebi was one of the early employees at Tularik, Inc., where he conducted drug discovery and basic research for an anti-viral drug program. Mr. Celebi received an M.B.A. from Carnegie Mellon University and a B.S. in Biophysics from the University of California, San Diego.

Mark Lee Ford leads business turnarounds of companies in industries such as financial services and consumer products. Based in Tokyo and Hong Kong, he also educates young entrepreneurs in the region by serving as a business school professor. Dr. Ford’s scientific interests include fluid mechanics and oncology. He received his BSc degree in Astrophysics from Trinity College, University of Toronto, MS and Ph.D. degrees in Aerospace Engineering from Boston University, and MBA degree from Duke University.

Hossein Ghanbari is a co-founder of Sensei Biotherapeutics and currently serves as its Chief Science Officer and Board Chair.  He served as Chairman, CEO and CSO of the company until February 2018 during which he led the company into clinical studies with SNS-301 and was instrumental in raising significant financing for the company.  Dr. Ghanbari began his career in the pharmaceutical industry at Abbott Laboratories in Chicago, where he developed several pharmaceuticals and the first ever commercialized diagnostic test for Alzheimer’s Disease (AD).  He was part of the New Drug Application (NDA) team for Leupron, the successful prostate cancer drug, as well as for Survanta, the current drug of choice for preventing and treating respiratory distress syndrome in premature infants.  He directed the Analytical sections of the Investigational New Drug (IND) application for an antibody-based antiviral drug and was a member of Abbott’s Technical Advisory Board.  Dr. Ghanbari was inducted into the prestigious honorary organization, the Volwiler Society, established by Abbott to recognize the company’s most distinguished and accomplished scientists.  After nearly a decade with Abbott, Dr. Ghanbari left to form Molecular Geriatrics Corporation, (a biopharma company focused on developing drugs for neurodegenerative diseases) and served as its Senior Vice-President for R&D.  Subsequently, Dr. Ghanbari was instrumental in establishing Nymox Pharmaceutical Corporation (NASDAQ: NYMX), and served as Senior Vice-President for R&D and Strategic Planning as well as a Director on its board.  While with Nymox, he developed the first commercially available cerebral spinal fluid- and urine-based diagnostics tests for Alzheimer’s Disease (AD) and identified opportunities for complementary technologies that Nymox in-licensed, which together established the company’s international presence as a leader in AD diagnostics and therapeutics.  Prior to entering private industry, Dr. Ghanbari held professorships at Pennsylvania State University, University of Florida, and Arya-Mehr University of Technology (now Sharif University).  He was also on the academic staff of The George Washington University School of Medicine and Health Sciences as an Adjunct Professor.  He currently serves as a Board member of the Gastric Cancer Foundation.  Dr. Ghanbari received his Bachelor of Sciences degree, with distinction, from the American University in Beirut, and his master’s and doctorate degrees in Biochemistry from Pennsylvania State University.  He has authored over 70 peer reviewed publications, and is an inventor on nearly 100 patents and patent applications worldwide.

Mehdi Hatamian received his B.S.  degree in Electrical Engineering from Sharif University of Technology in 1977, and M.S. and Ph.D. degrees in Electrical Engineering from the University of Michigan in Ann Arbor, in 1978 and 1982 respectively.  Most recently, Dr. Hatamian was Chief Scientist of Central Engineering and Fellow at Broadcom Limited, and Senior VP Engineering at Broadcom Corporation. Previously, Dr. Hatamian worked for NASA’s Space Shuttle program, developing hardware and software designs to support in-flight biomedical experiments. He was a member of the Visual Communications Research and the VLSI Systems Research departments of Bell Laboratories, where he was named Distinguished Member of the Technical Staff. He also served as Vice President of Technology at Silicon Design Experts (SDE), Inc., a company he co-founded. SDE was acquired by Level One Corp. which was later acquired by Intel Corp.  He has published 50 papers and holds 94 issued patents with several patents pending.  Dr. Hatamian has been inducted in the National Academy of Engineering for his contributions to the development of integrated circuits for video, communications, and digital signal processing. He is a Fellow member of the Institute of Electrical and Electronics Engineers (IEEE). Dr. Hatamian received the “#1 Patent Holder” award from Broadcom Corp. and the Broadcom Fellow award. He received the University of Michigan’s ECE Division Alumni Merit Award for 2008. He served on the Engineering Advisory Council of the University of Michigan. He has participated in numerous national and international conferences and other professional activities in his field as keynote speaker, organizer, session chair, panelist, invited lecturer, and moderator. In addition to Sensei Bio, Dr. Hatamian has served on the board of directors of PharmacoKinesis, Inc.

Mr. Holmen has over 25 years’ experience working in and advising technology, healthcare and financial services companies.  He has engaged at every phase of corporate development, from formation to financing to operations to exiting, and has served in diverse roles from electrical engineer (Hughes Aircraft) to an associate at major law firms (Latham &Watkins, Morrison & Foerster) to general counsel for a series of technology and financial services companies to co-founder and managing director for a family of venture funds (Miramar Venture Partners).

Currently, Mr. Holmen provides legal services to investors through his boutique law firm Investor Counsel, focused on the venture capital and private equity markets.  His work encompasses fund formation, financing and operations, structuring and negotiating investments, mergers and acquisition, and purchaser representation.  In addition, he continues to serve as a Managing Director for the legacy (fully invested) Miramar Venture Partners funds.  Mr. Holmen also has served as an adjunct professor, teaching “Venture Capital Law” at the UC, Irvine Law School and “Investing in New Ventures” at USC’s Marshall School of Business, in addition to writing about venture and M&A matters.  He received his B.S. in Electrical Engineering from Stanford University and his J.D. from UC Berkeley School of Law (Boalt Hall).

Tom Ricks has been a member of the Board of Directors since 2015. Mr. Ricks currently serves as Chief Investment Officer of H&S Ventures LLC, a private investment firm. Prior to taking this position with H&S Ventures, he was Chief Executive Officer of The University of Texas Investment Management Company. Mr. Ricks also served as Vice Chancellor for Asset Management for The University of Texas System and as Executive Director of Finance and Private Investments. He has been a director of Newfield Exploration Company (NYSE:NFX) since 1992 and is Chairman of its Audit Committee. He is a former director of BDM International, DTM Corporation, LifeCell Corporation and Argus Pharmaceuticals. Mr. Ricks also serves on the Investment Committee of the University of California Foundation, Irvine and previously served on the board of the Ocean Institute.   Mr. Ricks holds a B.A. in Economics from Trinity College, an M.B.A. from the University of Chicago.